Suh Hyeon Jeong, Kim Inho, Cho Joo Youn, Park Sang In, Yoon Seo Hyun, Lee Jeong Ok, Koh Youngil, Song Kyoung Ho, Choe Pyoeng Gyun, Yu Kyung Sang, Kim Eu Suk, Kim Hong Bin, Bang Soo Mee, Kim Nam Joong, Song Sang Hoon, Park Wan Beom, Oh Myoung Don
Department of Internal Medicine, Seoul National University College of Medicine and Seoul National University Hospital, Seoul, Korea.
Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Seoul National University Hospital, Seoul, Korea.
Infect Chemother. 2017 Jun;49(2):135-139. doi: 10.3947/ic.2017.49.2.135. Epub 2017 Jun 9.
The posaconazole tablet formulation was developed to have improved bioavailability compared to the oral suspension. Here, we compared posaconazole plasma concentration (PPC) with the posaconazole oral suspension versus the tablet in Korean patients undergoing remission induction chemotherapy for hematologic malignancies. PPC was measured at 3, 8, and 15 days of treatment with the oral suspension (174 patients) or the tablet (40 patients). At all time-points, mean PPC was significantly higher with the tablet compared to the oral suspension. Our findings suggest that posaconazole tablets generate an optimal PPC earlier and in more patients than the oral suspension among Korean patients.
泊沙康唑片剂配方的研发旨在使其生物利用度比口服混悬液有所提高。在此，我们比较了在接受血液系统恶性肿瘤缓解诱导化疗的韩国患者中，泊沙康唑口服混悬液与片剂的血浆浓度（PPC）。在使用口服混悬液（174例患者）或片剂（40例患者）治疗的第3、8和15天测量PPC。在所有时间点，与口服混悬液相比，片剂的平均PPC显著更高。我们的研究结果表明，在韩国患者中，泊沙康唑片剂比口服混悬液更早且在更多患者中产生最佳PPC。
